EyePoint’s DURAVYU Misses LUCIA Phase 3 Primary Endpoint
On October 19, 2026, EyePoint reported topline results from LUCIA, a Phase 3 trial of investigational DURAVYU in wet age-related macular degeneration. DURAVYU did not achieve statistical non-inferiority to on-label 2 mg aflibercept in mean change in best-corrected visual acuity, although EyePoint reported key secondary results including a 38% reduction in treatment burden and 52% of eyes requiring no supplemental treatment through Week 56. EyePoint said it would conduct additional analyses to assess next steps for DURAVYU in wet AMD.
EyePoint’s October 19, 2026 topline report is a new, forward-looking Phase 3 clinical result: DURAVYU failed the LUCIA primary non-inferiority endpoint against on-label aflibercept, materially reducing the probability and timing of wet-AMD approval and commercialization despite positive secondary findings. I classify it as clinical_study because the core update is a trial result; importance is high but company-specific, while surprise is moderated by the earlier LUGANO primary-endpoint miss. Confidence is high because the trial result and date are explicitly reported, although the exact UTC time is inferred from the contemporaneous source timestamp. Stakeholder approval is limited to EYPT and the directly exposed aflibercept franchise holders REGN and BAYRY; other competitive read-throughs are too indirect or ambiguous.
LUCIA did not achieve primary endpoint of statistical non‑inferiority in mean change in BCVA vs on‑label aflibercept.
Key secondary endpoints met: 38% reduction in treatment burden (nominal p<0.0001); 52% supplement‑free at Week 56.